Rapport Therapeutics Conference Call Summary Company Overview - Company: Rapport Therapeutics (NasdaqGM:RAPP) - Focus: Precision neuroscience, specifically targeting receptor-associated proteins related to AMPA receptors, which are crucial in the treatment of epilepsy [2][4] Key Points and Arguments Unique Mechanism of Action - Rapport Therapeutics is developing RAP-219, which targets TARP gamma 8, an auxiliary protein associated with AMPA receptors, selectively expressed in brain regions critical for focal-onset seizures [3][4] - This selectivity allows for a higher therapeutic index compared to traditional anti-seizure medications, which often have low therapeutic indices and significant side effects [4][10] Clinical Data and Efficacy - The company reported a 72% reduction in long episodes of electrographic seizures and a 78% median reduction in clinical seizures during their proof of concept study [13] - A 24% seizure freedom rate was observed from day 1 to day 56 in the trial [14] - The innovative use of the RNS System for continuous monitoring of electrographic activity allowed for a more efficient study design, reducing the required sample size to 30 patients [16][12] Tolerability Profile - RAP-219 demonstrated a favorable tolerability profile with a 10% discontinuation rate, which is low for focal epilepsy trials [30] - Common adverse events included dizziness and headache, typical of anti-seizure medications, but were generally mild to moderate [30] Phase 3 Study Plans - Two parallel Phase 3 studies are set to begin in Q2 2026, exploring different dosing strategies (0.25 mg and 0.75 mg in one study, 0.75 mg and 1.25 mg in another) [41] - The studies aim to confirm the efficacy seen in Phase 2 and will include a titration schema over 7-9 days [42] Strategic Partnerships and Market Position - A partnership with Tenacia in China was established, providing a $20 million upfront payment and potential for $308 million in biobucks and royalties, which will support development in the region [53] - The partnership allows for patient recruitment in China, which has historically been inaccessible for such trials [52] Future Indications and Pipeline - The company plans to expand RAP-219's indications to include primary generalized tonic-clonic seizures and is also exploring its use in bipolar mania, with data expected in 2027 [111][112] - The long-acting injectable (LAI) formulation of RAP-219 is in development, with potential human PK results expected in 2027, which could transform treatment options for epilepsy patients [93][94] Financial Outlook - Rapport Therapeutics has sufficient cash runway into the second half of 2029, allowing for the completion of ongoing studies and the initiation of new trials [121] Additional Important Insights - The company believes that the unique mechanism and efficacy of RAP-219 could position it as a best-in-class therapy for focal-onset seizures [81][88] - The potential for a long-acting injectable formulation could address significant patient needs and extend the revenue durability of the product [96][100] This summary encapsulates the key points discussed during the conference call, highlighting the innovative approach of Rapport Therapeutics in the epilepsy treatment landscape and its strategic plans for future growth and development.
Rapport Therapeutics (NasdaqGM:RAPP) 2026 Conference Transcript